History

& Key Facts

2023

ANTABIO Raises €25 million in Series B Financing. Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 up to completion of Phase 2 trials.

2023

Start of the Phase 1 clinical trial of MEM-ANT3310, Antabio’s lead program being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE)

2022

Launch of ARPEGE, a multidisciplinary AMR consortium led by Antabio with €5.5m public funding to support the development of MEM-ANT3310 towards clinical studies

2020

FDA grants Qualified Infectious Disease Product (QIDP) designation to MEM-ANT3310 for major hospital indications including nosocomial pneumonia

2019

CARB-X renews support for ANT3273 further to the completion of the first stage milestones. $4.4 Million awarded up to the completion of non-GLP preclinical studies

2019

FDA grants Qualified Infectious Disease Product (QIDP) designation to MEM-ANT2681 for the treatment of complicated urinary tract infections (cUTI)

2018

Antabio completes €12.5m Series A

2017

CARB-X awards Antabio ANT3273 with funding of up to $2.8 million with options for up to $8.9 million upon achievement of milestones

2015

The Wellcome Trust awards Antabio €4.0 million Seeding Drug Discovery Award for the development of a small molecule inhibitor of Pseudomonoas aeruginosa biofilms (ANT3273)

2013

The Wellcome Trust awards Antabio €4.7 million Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria (MEM-ANT2681)

Menu